HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahaly, G. Articles by Bockisch, A. Search for Related Content PubMed PubMed Citation Articles by Kahaly, G. Articles by Bockisch, A.

Indium-111-Pentetreotide Scintigraphy in Graves' Ophthalmopathy

Departments of Endocrinology/Metabolism and Nuclear Medicine, Johannes Gutenberg-University Hospital, Mainz, Germany

Correspondence: For correspondence or reprints contact: George Kahaly, MD, PD, Dept. of Endocrinology/Metabolism, Bldg 303, University Hospital, 55101 Mainz, Germany.

ABSTRACT

The radiolabeled somatostatin analog ¹¹¹In-pentetreotide can sensitively demonstrate somatostatin receptor-positive localizations in diseases where activated lymphocytes play a role. Lymphocyte infiltration of retrobulbar tissue in Graves' ophthalmopathy is the rationale of receptor imaging with radionuclide coupled ¹¹¹In-pentetreotide. Method: Forty patients with Graves' ophthalmopathy, 5 patients with orbital myositis and 10 control subjects were included in this prospective study. Indium-111-pentetreotide (110 MBq) was intravenously injected and SPECT images were obtained at 4 and 24 hr after injection. The scans were analyzed by a region of interest technique. An uptake ratio between the orbits and the brain was determined. Results: Compared to controls (4-hr ¹¹¹In-pentetreotide uptake: median 6.0 counts/voxel/MBq, orbit-to-brain ratio 5.6), ophthalmopathy patients showed two- to threefold increased uptake (15.8 counts/voxel/MBq versus controls p = 0.0032; ratio 12.6 versus controls p = 0.003). When considering patients with active disease only, even higher uptake was registered (16.8 counts/voxel/MBq versus controls p = 0.0048, ratio 15.6 versus controls p = 0.0006). Untreated patients showed markedly higher uptake (23 counts/voxel/MBq) compared to patients under steroid therapy (12.6, p = 0.001). In myositis, high uptake (20 counts/voxel/MBq) was also registered. Conclusion: In contrast to controls, ophthalmopathy patients showed markedly increased orbital accumulation of labeled ¹¹¹In-pentetreotide. This sensitive nuclear medicine technique could possibly select those patients who might benefit from treatment with immunosuppressive agents and/or octreotide.

Key Words: indium-111-pentetreotide • Graves' ophthalmopathy • somatostatin receptor scintigraphy

This article has been cited by other articles:

				S. Savastano, R. Pivonello, W. Acampa, M. Salvatore, G. Lombardi, A. Colao, and G. Fenzi Recombinant Thyrotropin-Induced Orbital Uptake of [111In-Diethylenetriamine-Pentacetic Acid-D-Phe1]Octreotide in a Patient with Inactive Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2440 - 2444. [Abstract] [Full Text] [PDF]

				L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]

				C. Hansen, R. Rouhi, G. Förster, and G. J. Kahaly Increased Sulfatation of Orbital Glycosaminoglycans in Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1409 - 1413. [Abstract] [Full Text]